Differences of humoral and cellular immune response to an acellular pertussis booster in adolescents with a whole cell or acellular primary vaccination

Vaccine

Volumn 26, Issue 52, 2008, Pages 6929-6935

  Rieber, Nikolaus ^a   Graf, Anna ^a   Belohradsky, Bernd H ^a   Hartl, Dominik ^a   Urschel, Simon ^a   Riffelmann, Marion ^b   Wirsing von König, Carl Heinz ^b   Liese, Johannes ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b HELIOS KLINIKUM KREFELD   (Germany)

Author keywords

Adolescents; Cell mediated immunity; Pertussis vaccination

Indexed keywords

DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; HEMAGGLUTININ; IMPFSTOFF; IPV MERIEUX; PERTACTIN; PERTUSSIS TOXIN; PERTUSSIS VACCINE; POLIOMYELITIS VACCINE; UNCLASSIFIED DRUG;

ANTIBODY TITER; ARTICLE; B LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL TRIAL; FIMBRIA; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; LYMPHOCYTE PROLIFERATION; MEMORY CELL; MULTICENTER STUDY; PERTUSSIS; PRIORITY JOURNAL; VACCINATION;

ADOLESCENT; ANTIBODIES, BACTERIAL; ANTIBODY FORMATION; CELL PROLIFERATION; CHILD; CHILD, PRESCHOOL; FEMALE; GERMANY; HUMANS; IMMUNITY, CELLULAR; IMMUNIZATION, SECONDARY; IMMUNOGLOBULIN G; INFANT; LYMPHOCYTES; MALE; MONOCYTES; PERTUSSIS VACCINE; VACCINES, ACELLULAR;

EID: 56649121903     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.09.064     Document Type: Article

References (36)

1. Centers for Disease Control and Prevention. Summary of notifiable diseases-United States, 2005. Published March 30, 2007, for MMWR 2005;54(53):77-9.
2. Yih W.K., Lett S.M., des Vignes F.N., Garrison K.M., Sipe P.L., and Marchant C.D. The increasing incidence of pertussis in Massachusetts adolescents and adults 1989-1998. J Infect Dis 182 5 (2000) 1409-1416
3. Wirsing von König C.H., Halperin S., Riffelmann M., and Guiso N. Pertussis of adults and infants. Lancet Infect Dis 2 12 (2002) 744-750
4. Riffelmann M., Littmann M., Hulsse C., O'Brien J., and Wirsing von König C.H. Pertussis: incidence, symptoms and costs. Dtsch Med Wochenschr 131 50 (2006) 2829-2834
5. Deen J.L., Mink C.A., Cherry J.D., Christenson P.D., Pineda E.F., Lewis K., et al. Household contact study of Bordetella pertussis infections. Clin Infect Dis 21 5 (1995) 1211-1219
6. Wendelboe A.M., Njamkepo E., Bourillon A., Floret D.D., Gaudelus J., Gerber M., et al. Transmission of Bordetella pertussis to young infants. Pediatr Infect Dis J 26 4 (2007) 293-299
7. Tanaka M., Vitek C.R., Pascual F.B., Bisgard K.M., Tate J.E., and Murphy T.V. Trends in pertussis among infants in the United States 1980-1999. JAMA 290 22 (2003) 2968-2975
8. Vitek C.R., Pascual F.B., Baughman A.L., and Murphy T.V. Increase in deaths from pertussis among young infants in the United States in the 1990s. Pediatr Infect Dis J 22 7 (2003) 628-634
9. Edwards K.M., and Decker M.D. Pertussis vaccine. In: Plotkin S.A., Orenstein W.A., and Offit P.A. (Eds). Vaccines. 5th ed. (2008), Saunders, Philadelphia 467-517
10. Liese J.G., Meschievitz C.K., Harzer E., Froeschle J., Hosbach P., Hoppe J.E., et al. Efficacy of a two-component acellular pertussis vaccine in infants. Pediatr Infect Dis J 16 11 (1997) 1038-1044
11. Ryan M., Murphy G., Ryan E., Nilsson L., Shackley F., Gothefors L., et al. Distinct T-cell subtypes induced with whole cell and acellular pertussis vaccines in children. Immunology 93 1 (1998) 1-10
12. Esposito S., Agliardi T., Giammanco A., Faldella G., Cascio A., Bosis S., et al. Long-term pertussis-specific immunity after primary vaccination with a combined diphtheria, tetanus, tricomponent acellular pertussis, and hepatitis B vaccine in comparison with that after natural infection. Infect Immun 69 7 (2001) 4516-4520
13. Redhead K., Watkins J., Barnard A., and Mills K.H. Effective immunization against Bordetella pertussis respiratory infection in mice is dependent on induction of cell-mediated immunity. Infect Immun 61 8 (1993) 3190-3198
14. Pichichero M.E., Francis A.B., Marsocci S.M., Green J.L., Disney F.A., and Meschievitz C. Safety and immunogenicity of an acellular pertussis vaccine booster in 15- to 20-month-old children previously immunized with acellular or whole-cell pertussis vaccine as infants. Pediatrics 91 4 (1993) 756-760
15. Ausiello C.M., Lande R., Urbani F., la Sala A., Stefanelli P., Salmaso S., et al. Cell-mediated immune responses in four-year-old children after primary immunization with acellular pertussis vaccines. Infect Immun 67 8 (1999) 4064-4071
16. Edelman K.J., He Q., Makinen J.P., Haanpera M.S., Nguyen Tran Minh N., Schuerman L., et al. Pertussis-specific cell-mediated and humoral immunity in adolescents 3 years after booster immunization with acellular pertussis vaccine. Clin Infect Dis 39 2 (2004) 179-185
17. Edelman K., He Q., Makinen J., Sahlberg A., Haanpera M., Schuerman L., et al. Immunity to pertussis 5 years after booster immunization during adolescence. Clin Infect Dis 44 10 (2007) 1271-1277
18. Meyer C.U., Zepp F., Decker M., Lee M., Chang S.J., Ward J., et al. Cellular immunity in adolescents and adults following acellular pertussis vaccine administration. Clin Vac Immunol 14 3 (2007) 288-292
19. Pichichero M.E., Casey J.R., Francis A.B., Marsocci S.M., Murphy M., Hoeger W., et al. Acellular pertussis vaccine boosters combined with diphtheria and tetanus toxoid boosters for adolescents: safety and immunogenicity assessment when preceded by different 5-dose DTaP/DTwP schedules. Clin Pediatr (Phila) 45 7 (2006) 613-620
20. Liese J.G., Stojanov S., Zink T.H., Froeschle J., Klepadlo R., Kronwitter A., et al. Safety and immunogenicity of Biken acellular pertussis vaccine in combination with diphtheria and tetanus toxoid as a fifth dose at four to six years of age. Munich Vaccine Study Group. Pediatr Infect Dis J 20 10 (2001) 981-988
21. Liese, J. Clinical trial report TRI05, EUDRACT-number 2005-003765-17; 2007.
22. Wirsing von König C.H., Gounis D., Laukamp S., Bogaerts H., and Schmitt H.J. Evaluation of a single-sample serological technique for diagnosing pertussis in unvaccinated children. Eur J Clin Microbiol Infect Dis 18 5 (1999) 341-345
23. Zepp F., Knuf M., Habermehl P., Schmitt J.H., Rebsch C., Schmidtke P., et al. Pertussis-specific cell-mediated immunity in infants after vaccination with a tricomponent acellular pertussis vaccine. Infect Immun 64 10 (1996) 4078-4084
24. Baughman A.L., Bisgard K.M., Edwards K.M., Guris D., Decker M.D., Holland K., et al. Establishment of diagnostic cutoff points for levels of serum antibodies to pertussis toxin, filamentous hemagglutinin, and fimbriae in adolescents and adults in the United States. Clin Diagn Lab Immunol 11 6 (2004) 1045-1053
25. Liese J, Rieber N, Malzer T, Ocak M, Johnson DR, Decker MD. Safety of a sixth consecutive dose of tetanus-diphtheria-acellular pertussis vaccine in adolescents. Abstract for ICAAC 2007.
26. Tran Minh N.N., Edelman K., He Q., Viljanen M.K., Arvilommi H., and Mertsola J. Antibody and cell-mediated immune responses to booster immunization with a new acellular pertussis vaccine in school children. Vaccine 16 17 (1998) 1604-1610
27. Knuf M., Zepp F., Meyer C., Grzegowski E., Wolter J., Riffelmann M., et al. Immunogenicity of a single dose of reduced-antigen acellular pertussis vaccine in a non-vaccinated adolescent population. Vaccine 24 12 (2006) 2043-2048
28. Cassone A., Ausiello C.M., Urbani F., Lande R., Giuliano M., La Sala A., et al. Cell-mediated and antibody responses to Bordetella pertussis antigens in children vaccinated with acellular or whole-cell pertussis vaccines. The Progetto Pertosse-CMI Working Group. Arch Pediatr Adolesc Med 151 3 (1997) 283-289
29. Ausiello C.M., Lande R., Urbani F., Di Carlo B., Stefanelli P., Salmaso S., et al. Cell-mediated immunity and antibody responses to Bordetella pertussis antigens in children with a history of pertussis infection and in recipients of an acellular pertussis vaccine. J Infect Dis 181 6 (2000) 1989-1995
30. Vieira P., and Rajewsky K. Persistence of memory B cells in mice deprived of T cell help. Int Immunol 2 6 (1990) 487-494
31. Mills K.H., Barnard A., Watkins J., and Redhead K. Cell-mediated immunity to Bordetella pertussis: role of Th1 cells in bacterial clearance in a murine respiratory infection model. Infect Immun 61 2 (1993) 399-410
32. Mattoo S., and Cherry J.D. Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies. Clin Microbiol Rev 18 2 (2005) 326-382
33. Guiso N., Njamkepo E., Vie le Sage F., Zepp F., Meyer C.U., Abitbol V., et al. Long-term humoral and cell-mediated immunity after acellular pertussis vaccination compares favourably with whole-cell vaccines 6 years after booster vaccination in the second year of life. Vaccine 25 8 (2007) 1390-1397
34. Radbruch A., Muehlinghaus G., Luger E.O., Inamine A., Smith K.G., Dorner T., et al. Competence and competition: the challenge of becoming a long-lived plasma cell. Nat Rev Immunol 6 10 (2006) 741-750
35. Bernasconi N.L., Traggiai E., and Lanzavecchia A. Maintenance of serological memory by polyclonal activation of human memory B cells. Science 298 5601 (2002) 2199-2202
36. Raman V.S., Lind E.F., Benson M.J., and Noelle R.J. Strategies for selective priming of memory B cells. Immunol Lett 109 2 (2007) 93-100